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Abstract
Objectives: This study aims to assess the prevalence of clinical isolates of En-
terobacteriaceae with carbapenem resistance, and to characterize the types of 
carbapenemases produced.
Methods: Non-duplicate Enterobacteriaceae (Klebsiella spp, Enterobacter spp and 
E. coli) clinical isolates collected over 19 months (May 2009 through December 
2010) were included in this study. The modified Hodge test was performed on 
strains showing reduced ertapenem susceptibility. Isolates that tested positive were 
sent to the French reference center on emerging resistance for molecular charac-
terization and clone determination.
Results: A total of 463 strains were investigated: E. coli 63.9%, Klebsiella spp 
27.9% and Enterobacter spp 8.2%. Carbapenemase production occurred in 13 
isolates (2.8%). Ten strains produced class D carbapenemases (OXA-48). These 
included 6 K. pneumoniae, 1 K. oxytoca and 3 E. cloacae. New Delhi metallo-β-
lactamase-1 (NDM-1) was produced by three K. pneumoniae strains.
Conclusion: The high prevalence of carbapenemases producing Klebsiella and 
Enterobacter among clinical isolates and the detection of NDM-1 carbapenemase 
is a source of concern in Morocco. This feature requires setting up an emerging 
resistance monitoring and surveillance scheme at national level.
Keywords: Carbapenemases; Enterobacteriaceae; Klebsiella; Prevalence; Resis-
tance.
This article is available from: 
www.iajaa.org
Introduction
Over the past ten years, carbapenem resistant Enterobacteria-
ceae have been reported worldwide (1). The first carbapen-
emase producer in Enterobacteriaceae (NmcA) was identified 
in 1993 (2), since then, a large variety of carbapenemases has 
been identified in Enterobacteriaceae belonging to 3 classes 
of β-lactamases: the Ambler class A, B and D. 
The most frequently circulating carbapenemase among Medi-
terranean countries was the Ambler class D: OXA-48 type 
β-lactamase (3).The OXA-48 type was initially identified in 
2004 in a carbapenem resistant Klebsiella pneumonia iso-
late from Istanbul (4), and progressively disseminated to other 
Mediterranean areas including Lebanon,Tunisia, France and 
Morocco. The first case of K. pneumoniae OXA-48 resistant in 
Morocco was reported in 2009 (5). Other isolates of OXA-48 
producing Enterobacteriaceae were discovered in France and 
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Belgium, from patients who were transferred from Morocco 
(6,7). Recently a nosocomial occurrence of OXA-48 producing 
enterobacterial isolates was reported in Morocco and which 
showed the increased spread of OXA-48 Enterobacteriaceae 
in this country (8).
New Delhi metallo β-lactamase (NDM-1) is the latest carbap-
enemase to be discovered. It was first described in 2008 in K. 
pneumoniae and E. coli isolated in Sweden from an Indian pa-
tient transferred from a New Delhi hospital (9). Most positive 
NDM-1 bacterial isolates have shown epidemiological links to 
India and Pakistan (10). Recently, in 2010, three isolates of 
NDM-1 K. pneumoniae were reported in Morocco (11).
This study aims to assess the prevalence of carbapenemase 
producing strains in a main Moroccan hospital and to char-
acterize the enzymes produced.
Material and Methods
Study location
This prospective study carried out over the period ( May 2009 
to December 2010) at the Microbiology Laboratory of Cheikh 
Zaid University Hospital in Rabat, Morocco. The hospital has 
250 beds and an annual admission rate of nearly 3,000.
Bacterial strains 
All non-duplicate Klebsiella spp, E. coli, and Enterobacter spp 
clinical isolates from inpatients were included in this study. 
All isolates were identified to species level using (API 20 E®, 
bioMérieux, Marcy-l’Étoile, France).
Phenotype screening for carbapenemase 
production
All clinical isolates with a decreased inhibition diameter 
(≤26mm of 10µg ertapenem disk) using the diffusion method 
had their Minimum Inhibitory Concentration (MIC) evaluated 
using the E-TEST method (bioMérieux, Marcy-l’Étoile, France). 
Isolates that were found to show no susceptibility to ertap-
enem (MIC >0.5µg/ml; according to the European Commit-
tee on Antimicrobial Susceptibility Testing (EUCAST) recom-
mendations (12) were tested using the modified Hodge test, 
as recommended by the Clinical and Laboratory Standards 
Institute (CLSI) (13).
Phenotype determination of carbapenemase 
classes
All strains resistant to ertapenem and which were positive in 
the Hodge test underwent tests for carbapenemases activity 
inhibition. Class A enzyme production was investigated us-
ing the technique described by Doi et al. (14), which is based 
on 3-aminophenylboronic acid inhibition of carbapenemase 
activity. Class B carbapenemases were detected using the 
EDTA inhibition test. The inhibition diameters around a 10µg 
imipenem disk for the tested strains were compared to the 
diameters around another imipenem disk, to which had been 
added 750μg EDTA. An increase in the zone of inhibition to 
greater than or equal to 7mm was regarded as positive (15).
Molecular investigation
Strains that tested positive with the Hodge test were sent 
to the international expertise center for emerging resistance 
to antibiotics: INSERM Unit 914 for the molecular study, us-
ing PCR and sequencing to search for b-lactamase genes, in 
addition to the multilocus sequence typing and the pulsed-
field gel electrophoresis to determine the clonal relationships 
between the isolates (8,11).
First, specific primers were used for the detection of of the 
following carbapenemase genes: blaNDM, blaVIM, blaIMP, 
blaKPC and blaOXA-48 (8,11).
For those isolates positive for the blaOXA-48, all β-lactamase 
genes that had previously been identified in OXA-48-produc-
ing K. pneumoniae isolates ( blaTEM, blaSHV and blaCTX-
M ) were investigated together with the AmpC β-lactamase 
genes blaDHA and blaCMY, and corresponding amplicons 
were subsequently sequenced. Plasmid DNA extraction was 
performed according to the Kieser technique (16). The ge-
netic environment of the blaOXA-48 gene was determined 
by PCR mapping (8).
All negative isolates for the blaOXA-48 were screened for 
16S rRNA methylase-encoding genes using a multiplex PCR 
approach. Amplified DNA fragments were purified with the 
Qiaquick PCR purification kit (Qiagen, Courtaboeuf, France). 
Both strands of the amplification products obtained were 
sequenced with an ABI 3100 sequencer (Applied Biosystems, 
Foster City, CA, USA). The nucleotide and deduced protein 
sequences were analyzed with a software available over the 
Internet from the National Center for Biotechnology Informa-
tion web site (www.ncbi.nlm.nih.gov) (11).
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Antibiotic susceptibility profile determination
The MICs of carbapenems producing strains (imipenem, er-
tapenem and meropenem) was determined using the E-Test 
method. Susceptibility to other antibiotics was studied by the 
agar diffusion method according to EUCAST recommenda-
tions (12).
Results
Prevalence
A total of 463 clinical isolates were investigated, and E. coli 
isolates were accounted for 63.9% (296), followed by Klebsi-
ella spp for 27.9% (129) and Enterobacter spp for 8.2% (38). 
Thirteen isolates (2.8%) were positive in modified Hodge test 
but they were non-susceptible to ertapenem (MIC >0.5µg/
ml). These include 10 Klebsiella (9 K. pneumoniae, 1 K. oxy-
toca) and 3 Enterobacter cloacae strains which were repre-
sented a genus prevalence of 7.5% and 7.8%, respectively 
(Table 1). The isolates were recovered from 12 different pa-
tients; including two carbapenemase producing strains (one 
K. pneumoniae and one E. cloacae) were isolated from two 
different sampling sites of the same patient.
Carbapenemase classes produced
Non of the strain that tested positive in the Hodge test has 
produced any Class A carbapenemases . Also, three K. pneu-
moniae strains exhibited positive results in the EDTA inhibition 
test (Table 2). A total of 10/13 (76.9%) strains produced Class 
D (OXA-48) carbapenemases. Of these 7 were s Klebsiella (6 
K. pneumoniae, 1 K. oxytoca) and 3 E. cloacae strains. The 
other 3 K. pneumoniae strains (23%) produced Class B car-
bapenemases (NDM-1) .
Antibiotic susceptibility
Antibiotic susceptibility is shown in Table 2. 10 out 13 strains 
(76.9%) were susceptible to imipenem and meropenem. Pro-
duction of BLSE was found in all examined strains. Most iso-
lates were nearly complete resistance to the other antibiotic 
families, except for colimycin and fosfomycin (Table 3).
Discussion
In recent years worldwide, there is increased emerging of 
resistance to carbapenem among Enterobacteriaceae clinical 
isolates. These isolates were resistance to several antibiotic 
families and were associated with high mortality (17,18). The 
Table 1. Distribution of Hodge test positive isolates according to their isolation dates and the source of sampling.
Strains Isolation date Nature of sampling Bacterial species
1 07/03/2009 Blood culture E. cloacae
2 09/03/2009 Pus (postoperative wound) E. cloacae
3 09/04/2009 Subcutaneous fluid collection K. pneumoniae
4 09/24/2009 Urine K. pneumoniae
5 12/22/2009 Pus (postoperative wound)  E. cloacae
6 01/27/2010 Urine K. pneumoniae
7 08/13/2010 Catheter K. pneumoniae
8 09/28/2010 Urine K. pneumoniae
9 11/06/2010 Blood culture K. pneumoniae
10 12/01/2010 Urine K. pneumoniae
11 12/13/2010 Blood culture K. pneumoniae
12 12/20/2010 Pus (pancreas abscess) K. pneumoniae
13 12/28/2010 Urine K. oxytoca
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Table 2. MICs and molecular study of Hodge test positive strains. 
Strains
MIC (µg/ml)
PCR Clones
IMP ERT MER
1 0.5 1 0.25 OXA-48 EcA
2 0.5 1 0.25 OXA-48 EcA
3 0.5 3 0.38 OXA-48 Kp1
4 >32 >32 16 OXA-48 Kp2
5 2 16 2 OXA-48 EcB
6 1 2 0.5 OXA-48 Kp1
7 >32 >32 >32 OXA-48 Kp7
8 >32 >32 >32 OXA-48 Kp8
9 0.5 2 0.5 OXA-48 Kp2
10 1 4 2 NDM-1 ST15
11 1 4 2 NDM-1 ST15
12 1 4 2 NDM-1 ST15
13 1 4 1 OXA-48 ND
IMP: imipenem; ERT: ertapenem; MER: meropenem.
Table 3. Antibiotic susceptibility of carbapenemase-producing strains.
Strains IMP ERT TZP AMC CTX CRO CAZ CPO ATM FOS COS C GENT AN CIP SXT
1 S R R R R R S R  S S S I R R S R
2 S R R R R R R R R S S S R R S R
3 S R R R  R R R R R S S R R S R R
4 R R R R R R R R R S S S R I  R R
5 I R R R R R R R R S S R R R R R
6 S R R R R R R R R S S R R R R R
7 R R R R R R R R R S S I I S R R
8 S R R R R R R R R S S S R I R R
9 S R R R R R R R R S S S R S R R
10 S R R R R R R R R S S R R R R R
11 S R R R R R R R R S S R R R R R
12 S R R R R R R R R S S R R R R R
13 S R R R R R R R R S S R R S R R
IMP: imipenem 10 ug ; ERT: ertapenèm 10 ug ; TZP: piperacilline/tazobactam 75/10 ug ; AMC: amoxicillin/clavulanic acid 30 ug ; 
CTX: cefotaxime 30 ug ; CRO: ceftriaxone 30 ug ; CAZ: ceftazidime 30 ug ; CPO: cefpirome 30 ug ; ATM: aztreonam 30 ug ; FOS: 
fosfomycin 50 ug; COS: colistin 50 ug ; C: chloramphenicol 30 ug ; GENT: gentamicin 30 ug ; AN: amikacin 30ug ; CIP: ciprofloxacin 5 
ug ; SXT: sulfametoxazole/trimetoprim 1,25/23,75 ug. 
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increased prevalence of carbapenem-resistance of Entero-
bacteriaceae members in hospital environment constitutes a 
serious threat for hospitalized patients and to control their 
nosocomial infection.
The rate of carbapenemase producing Enterobacteriaceae in 
our study is 2.8%. Most published studies can’t be com-
pared with our results since these were reported epidemic 
outbreaks of infection due to carbapenem-resistance Klebsi-
ella spp. and E.coli strains. According to data from the Euro-
pean Antimicrobial Resistance Surveillance Network (EARS.
Net, formerly EARSS), the rates of carbapenemase producing 
K. pneumoniae in 2009 reached 43.5% in Greece, 17% in 
Cyprus, 1.3% in Italy, and 1.2% in Belgium, whereas less 
than 1% was reported from 23 other European countries (6). 
Investigation of our isolates genotypes demonstrated that 3 K. 
pneumoniae strains host a plasmid which carries a gene cod-
ing for an NDM-1-type β metallo enzyme. These strains were 
isolated from patients who had not visited India or Pakistan as 
the case with most other reported studies (19,20).
This study showed a high frequency (10 /13) of OXA-48 pro-
ducing strains among Klebsiella and Enterobacter spp. In Mo-
rocco, the first K. pneumoniae strain testing positive for OXA-
48 was isolated in our laboratory in 2009 (5). Other OXA-48 
Enterobacter cloacae strains have since then been isolated, 
especially in France, from patients of Moroccan origin (6). It ap-
pears from the molecular epidemiology investigation that our 
carbapenem resistant isolates belong to various clones, which 
suggests an endemic spreading of these strains in our country. 
Enterobacteriaceae isolates which carry genes coding for car-
bapenems are not always resistant to every carbapenem in 
vitro, although many ertapenem resistant strains may remain 
susceptible to other carbapenems in vitro (21).
In this study, most carbapenemase producing strains showed 
susceptibility to imipenem and/or meropenem (Table 2). 
However, therapeutic efficacy against infections with carbap-
enemase producing bacteria which are showing a susceptible 
carbapenem MIC is controversial. Treatment failure has been 
reported by some authors due to infection with susceptible 
carbapenem MIC Klebsiella producing carbapenemase (22, 
23). Others studies found no significant difference in mortal-
ity when imipenem MIC of Klebsiella pneumoniae is ≤4µg/ml 
in septicemia cases with or without carbapenemase produc-
tion, but a significant increased mortality has been observed 
when MIC was >4µg/ml (24,25).
Conclusion
Carbapenemase producing K. pneumoniae and Enterobac-
ter cloacae strains constitute a high proportion of bacteria 
isolates in Cheikh Zaid International University hospital. Early 
detection of K. pneumoniae (NDM-1) is epidemiologically and 
therapeutically important task in clinical laboratory. In addi-
tion, it is highly important to prevent the spread of carbap-
enemase producing strains among hospitalized patients by 
using extensive infection control measurement. 
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